Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Go back to Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management| (NASDAQ: VANI) | Delayed: 1.38 -0.11 (7.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.49 | 52 Week High | $ | |||
| Open | $1.50 | 52 Week Low | $ | |||
| Day High | $1.50 | P/E | N/A | |||
| Day Low | $1.34 | EPS | $ | |||
| Volume | 411,893 | |||||
